As part of the reorganization initiative, Nektar "also announced several changes to its executive team: Dr. Brian Kotzin, Nektar’s Chief Medical Officer, will be stepping down from his full-time role but will continue to serve in an ongoing role as a strategic advisor to the company. Dr. Mary Tagliaferri, current Chief Development Officer, will assume the role of Chief Medical Officer. Jillian Thomsen will be stepping down from her role as Chief Financial Officer (CFO) and will depart the company in June following a transition period. The company has appointed Sandra Gardiner to the role of acting CFO. Sandra is a skilled business and finance executive with over 30 years of financial and accounting experience. She is a partner at FLG Partners, a leading CFO services firm in Silicon Valley. Kevin Brodbeck, Nektar’s SVP of Technical Operations, will depart the company in June following a transition period. Ken Franke, current VP of Biologics Development & Manufacturing will assume Kevin’s responsibilities."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NKTR:
- Nektar Therapeutics says no cash deposits, securities at Silicon Valley Bank
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
- Nektar reports Q4 EPS (32c), consensus (45c)
- Nektar price target lowered to $3 from $5 at SVB Securities
- Nektar Plunges after Topline Data Misses Primary Endpoint